Evidence map›Paper›PMID 40667563›Full record

ArticleAmerican journal of cancer research2025

PINX1 inhibits proliferation and cisplatin resistance in nasopharyngeal carcinoma by promoting ILF3 ubiquitination.

Ni Zhou, Pinggui Gong, Shuilian Wang, Cui He, Liya Hu, Hong Peng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ni ZhouThe Second School of Clinical Medicine, Southern Medical University Guangzhou 510515, Guangdong, China.
Pinggui GongThe Second School of Clinical Medicine, Southern Medical University Guangzhou 510515, Guangdong, China.
Shuilian WangDepartment of Otolaryngology-Head and Neck Surgery, Foshan Women and Children Hospital Foshan 528000, Guangdong, China.
Cui HeThe Second School of Clinical Medicine, Southern Medical University Guangzhou 510515, Guangdong, China.
Liya HuThe Second School of Clinical Medicine, Southern Medical University Guangzhou 510515, Guangdong, China.
Hong PengThe Second School of Clinical Medicine, Southern Medical University Guangzhou 510515, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PIN2/TRF1-interacting telomerase inhibitor 1 (PINX1) acts as a tumor suppressor in various cancers, yet its molecular role in nasopharyngeal carcinoma (NPC) remains poorly defined. This study investigates the therapeutic potential of PINX1 in NPC. Expression levels of PINX1 and interleukin enhancer-binding factor 3 (ILF3) were assessed in NPC cells and tissues via western blotting and immunohistochemistry, and their correlation with patient prognosis was analyzed. The effects of ILF3 on NPC cell proliferation and cisplatin resistance were evaluated using cell cycle analysis, EdU incorporation, CCK-8, and IC

Indexed as

cisplatin resistanceILF3Nasopharyngeal carcinomaPINX1proliferationubiquitination

Identifiers

PMID40667563
PMCPMC12256408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.